 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...507508509510511512513514515516517...521522» |
- | New P2 trial: A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer (clinicaltrials.gov) - Aug 5, 2013
P2, N=80, Active, not recruiting, Sponsor: Fan Ming
- Enrollment closed: A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer (clinicaltrials.gov) - Aug 5, 2013
P2, N=80, Active, not recruiting, Sponsor: Fan Ming
Not yet recruiting --> Active, not recruiting
- | Trial completion: Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 5, 2013
P3, N=200, Completed, Sponsor: Cancer Research Campaign Clinical Trials Centre
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
New P3 trial: BCSMANC: Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (clinicaltrials.gov) - Aug 4, 2013
P3, N=4, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
- Rituxan (rituximab) / Roche
New P2 trial: Dose-adjusted EPOCH-R in MYC Positive DLBCL (clinicaltrials.gov) - Jul 31, 2013
P2, N=26, Recruiting, Sponsor: Fudan University
- |||| GSK2302024A / GSK
Enrollment open: INDUCT: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (clinicaltrials.gov) - Jul 31, 2013
P2, N=250, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 31, 2013
P2, N=109, Completed, Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Jul 31, 2013
P2, N=0, Completed, Sponsor: Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Trial completion: Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer (clinicaltrials.gov) - Jul 31, 2013
P3, N=400, Completed, Sponsor: Nordic Society for Gynaecologic Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | tamoxifen / Generic mfg.
Trial completion: Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer (clinicaltrials.gov) - Jul 31, 2013
P3, N=6000, Completed, Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Trial completion: Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL (clinicaltrials.gov) - Jul 30, 2013
P3, N=348, Completed, Sponsor: Fudan University
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Chemotherapeutic Agents in Brain/Breast (clinicaltrials.gov) - Jul 30, 2013
P=N/A, N=10, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- Oncaspar liquid (pegaspargase) / Servier, Marqibo (vincristine liposomal) / Servier, Aurobindo
Clinical: Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 28, 2013
P2, N=11, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Increased rate of bacterial infections
- Oncaspar liquid (pegaspargase) / Servier, Marqibo (vincristine liposomal) / Servier, Aurobindo
Clinical: Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 28, 2013
P2, N=11, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Terminated; Increased rate of bacterial infections N=30 --> 11
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open, Metastases: Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=40, Recruiting, Sponsor: Seoul National University Hospital
N=30 --> 11 Not yet recruiting --> Recruiting
- ||| Xalkori (crizotinib) / Pfizer
Enrollment open, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Jul 24, 2013
P1, N=58, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Metastases: Treatment With Pazopanib for Neoadjuvant Breast Cancer (clinicaltrials.gov) - Jul 24, 2013
P2, N=101, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients (clinicaltrials.gov) - Jul 23, 2013
P2, N=190, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || sorafenib / Generic mfg.
New P2/3 trial, Metastases: Sorafenib Chemoembolization Evaluation Controlled Trial (clinicaltrials.gov) - Jul 22, 2013
P2/3, N=398, Recruiting, Sponsor: Fourth Military Medical University
- Enrollment closed: Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer (clinicaltrials.gov) - Jul 22, 2013
P1, N=24, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- doxorubicin hydrochloride / Generic mfg.
Enrollment open: Cardiac Fibrosis by CMR in Patients With Cancer (clinicaltrials.gov) - Jul 19, 2013
P0, N=77, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| doxorubicin hydrochloride / Generic mfg.
Trial completion, Combination therapy, Metastases: PICASSO III: Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2013
P3, N=447, Completed, Sponsor: Ziopharm
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| conatumumab (AMG 655) / Amgen
Trial completion, Combination therapy, Metastases: Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2013
P1/2, N=134, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 15, 2013
P3, N=620, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Active, not recruiting --> Completed N=450 --> 620
- paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial withdrawal: Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer (clinicaltrials.gov) - Jul 14, 2013
P3, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
N=450 --> 620 Recruiting --> Withdrawn
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: A Study of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 10, 2013
P2, N=164, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Withdrawn Active, not recruiting --> Completed
- ||||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change: TITAN: A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 9, 2013
P3, N=614, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed N=1800 --> 614
- mitomycin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination, Metastases: Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus (clinicaltrials.gov) - Jul 7, 2013
P2, N=30, Terminated, Sponsor: Gynecologic Oncology Group
N=1800 --> 614 Active, not recruiting --> Terminated
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma (clinicaltrials.gov) - Jul 7, 2013
P1, N=33, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial withdrawal, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Withdrawn
- obatoclax (GX 15-070) / Teva
Trial termination, Combination therapy: Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) - Jun 30, 2013
P1, N=22, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn Active, not recruiting --> Terminated
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial initiation date, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Initiation date: Oct 2001 --> Jan 2005
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium (clinicaltrials.gov) - Jun 30, 2013
P3, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2001 --> Jan 2005 N=660 --> 0
- | RG7112 / Roche
Trial completion, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 30, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
N=660 --> 0 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors (clinicaltrials.gov) - Jun 30, 2013
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Enrollment change, Combination therapy: AALL07P1: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=150 --> 60
- | aldoxorubicin (INNO-206) / LadRx
Enrollment change, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=14, Completed, Sponsor: CytRx
N=150 --> 60 N=27 --> 14
- doxorubicin hydrochloride / Generic mfg.
Enrollment change: Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 26, 2013
P4, N=18, Completed, Sponsor: Meir Medical Center
N=27 --> 14 N=30 --> 18
- ||||| Enrollment change, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=109, Active, not recruiting, Sponsor: Children's Oncology Group
N=30 --> 18 N=75 --> 109
- Enrollment change, Metastases: Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=75 --> 109 N=528 --> 0
- |||||||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P3 trial: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) (clinicaltrials.gov) - Jun 26, 2013
P3, N=160, Recruiting, Sponsor: Hoffmann-La Roche
- | aldoxorubicin (INNO-206) / LadRx
Trial completion, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=14, Completed, Sponsor: CytRx
N=528 --> 0 Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Pharmacokinetic Study of Doxorubicin in Children With Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=101, Completed, Sponsor: University Hospital Muenster
Active, not recruiting --> Completed Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 26, 2013
P4, N=18, Completed, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- RG7112 / Roche
Enrollment change, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 24, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed N=36 --> 23
- ||| melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=138, Recruiting, Sponsor: Children's Oncology Group
N=36 --> 23 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment open, Surgery: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Jun 19, 2013
P2, N=48, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- doxorubicin hydrochloride / Generic mfg.
New P2 trial: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer (clinicaltrials.gov) - Jun 18, 2013
P2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Trial termination, BRCA Biomarker, Surgery, Metastases: Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 17, 2013
P2, N=16, Terminated, Sponsor: National Cancer Centre, Singapore
Not yet recruiting --> Recruiting Recruiting --> Terminated
- ||||| dactinomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial initiation date, Surgery: Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor (clinicaltrials.gov) - Jun 17, 2013
P3, N=808, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Terminated Initiation date: Jun 2006 --> Oct 2006